Table 1 Clinical characteristics of postmortem cases
From: SGTA associates with intracellular aggregates in neurodegenerative diseases
Disease | Case number | Age at death (years) | Sex (M/F) | Disease duration (months) | SGTA-reactive inclusions |
|---|---|---|---|---|---|
SCA1 | 1 | 55 | F | 144 | Positive |
SCA1 | 2 | 71 | F | 492 | Positive |
SCA2 | 3 | 57 | M | 120 | Positive |
SCA2 | 4 | 48 | F | 252 | Positive |
SCA3 | 5 | 40 | F | 156 | Positive |
SCA3 | 6 | 51 | F | 240 | Negative |
SCA3 | 7 | 36 | M | 168 | Positive |
DRPLA | 8 | 46 | F | 131 | Positive |
PD | 9 | 82 | F | 155 | Negative |
PD | 10 | 94 | F | 324 | Negative |
PD | 11 | 82 | F | 66 | Negative |
PD | 12 | 58 | F | 228 | Negative |
MSA | 13 | 48 | M | 85 | Positive |
MSA | 14 | 75 | M | 84 | Positive |
MSA | 15 | 65 | F | 40 | Positive |
MSA | 16 | 79 | F | 48 | Positive |
ALS | 17 | 69 | F | 7 | Negative |
ALS | 18 | 64 | M | 36 | Negative |
ALS | 19 | 87 | M | 29 | Negative |
ALS | 20 | 61 | M | 9 | Negative |
ALS | 21 | 75 | F | 7 | Negative |
ALS | 22 | 72 | M | 20 | Negative |